Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy

Table 1 Baseline data of the patients with primary central nervous system lymphoma

Characteristic	N = 19
Age, yr	57 (27–81)
Sex, n (%)
Male	9 (47.4)
Female	10 (52.6)
ECOG-PS ≥ 2, n (%)	5 (26.3)
Invasion of deep intracranial areas, n (%)	16 (84.2)
High CSF protein concentration (> 450 mg/L), n (%)	11 (68.75)1
High LDH serum concentration (> 250 U/L), n (%)	1 (5.3)
IELSG risk score, n (%)
Low	3 (18.75)1
Intermediate	12 (75)1
High	1 (6.25)1
Follow-up time (mo)	14.7 (3.9–30)

¹Three patients refused lumbar puncture for personal reasons.

ECOG-PS: Eastern Cooperative Oncology Group performance score; CSF: Cerebrospinal fluid; LDH: Lactate dehydrogenase; IELSG: International Extranodal Lymphoma Study Group.